(VIANEWS) – The NASDAQ opens in less than five hours and NeuroMetrix‘s pre-market value is already 4.83% down.
NeuroMetrix’s last close was $1.45, 75.38% under its 52-week high of $5.89.
The last session, NASDAQ finished with NeuroMetrix (NURO) dropping 3.33% to $1.45. NASDAQ jumped 1.01% to $11,787.40, after four consecutive sessions in a row of gains, on what was an all-around bullish trend trading session.
About NeuroMetrix
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Earnings Per Share
As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.47%.
Moving Average
NeuroMetrix’s value is way under its 50-day moving average of $1.75 and way under its 200-day moving average of $2.50.
Revenue Growth
Year-on-year quarterly revenue growth declined by 4.7%, now sitting on 8.23M for the twelve trailing months.
More news about NeuroMetrix (NURO).
